Amphastar Pharmaceuticals (AMPH) Getting Somewhat Positive News Coverage, Analysis Shows

Media coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 12 out of 100, indicating that recent press coverage is very unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH) traded up 0.79% during mid-day trading on Friday, hitting $17.79. 237,364 shares of the stock were exchanged. The stock has a market cap of $813.66 million, a PE ratio of 93.63 and a beta of 1.68. The stock’s 50 day moving average is $16.10 and its 200 day moving average is $16.25. Amphastar Pharmaceuticals has a 52-week low of $12.05 and a 52-week high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Monday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.03. Amphastar Pharmaceuticals had a net margin of 3.54% and a return on equity of 2.69%. The firm had revenue of $56.67 million during the quarter, compared to analysts’ expectations of $63.74 million. During the same quarter last year, the company posted $0.12 earnings per share. Amphastar Pharmaceuticals’s revenue for the quarter was down 4.5% on a year-over-year basis. Analysts forecast that Amphastar Pharmaceuticals will post $0.40 EPS for the current fiscal year.

Several equities research analysts recently issued reports on the stock. Jefferies Group LLC set a $21.00 target price on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, April 20th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th. Raymond James Financial, Inc. downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the company from $21.00 to $18.00 in a research report on Tuesday, March 14th. Needham & Company LLC decreased their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, March 14th. Finally, Piper Jaffray Companies reduced their price target on shares of Amphastar Pharmaceuticals from $22.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $20.14.

COPYRIGHT VIOLATION WARNING: “Amphastar Pharmaceuticals (AMPH) Getting Somewhat Positive News Coverage, Analysis Shows” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2017/06/23/amphastar-pharmaceuticals-amph-earning-somewhat-positive-press-coverage-analysis-finds-updated.html.

In related news, Director Michael A. Zasloff sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $17.01, for a total transaction of $255,150.00. Following the completion of the sale, the director now owns 47,411 shares of the company’s stock, valued at approximately $806,461.11. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $17.07, for a total value of $170,700.00. Following the completion of the transaction, the director now owns 28,844 shares of the company’s stock, valued at approximately $492,367.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,982 shares of company stock valued at $735,850. Corporate insiders own 11.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply